Research Grade Anti-Human CD223/LAG3 (GSK2831781) (HB613166)

데이터시트 제품 공유 정보 복사

가격(USD): $

사양:

100ug
1mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트

개요

카탈로그 번호	HB613166
설명	Anti-Human CD223/LAG3 (GSK2831781) (HB613166) is a research-grade recombinant antibody targeting CD223. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
숙주 종	Human
이소타입	IgG1-kappa
클론 ID	GSK2831781
발현 시스템	Mammalian Cells
클론성	Monoclonal
타겟	FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3
내독소 수준	Please contact the lab for this information.
순도	>95% purity as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P18627
형태	Liquid
저장 완충액	0.01M PBS, pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
대체 이름	GSK2831781
배경	Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
참고사항	For research use only. Not suitable for clinical or therapeutic use.

이미지

SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD223/LAG3 (GSK2831781)
Bioactivity

Detects recombinant human CD223/LAG3 (Catalog No: HB613011) in indirect ELISA